Showing 2411-2420 of 2812 results for "".
- Bausch Health Suspends Plans for Solta IPOhttps://modernaesthetics.com/news/bausch-health-suspends-plans-for-solta-ipo-1/2473255/Bausch Health Companies Inc. is suspending its plans for the Solta IPO due to challenging market conditions and other factors. Bausch Health stated that the interests of the Company's stakeholders are best served in the near-term by focusing on driving Solta's revenue, profits a
- New from Senté: Even Tone Mineral Sunscreenhttps://modernaesthetics.com/news/new-from-sente-even-tone-mineral-sunscreen/2473252/Senté has launched new tinted sunscreen formulas that protect the skin from damage caused by visible light in addition to UV rays. Even Tone Mineral Sunscreen is specifically designed to promote even skin tone in every complexion, the company says.
- Top-line Phase 3 Data Promising for Galderma's RelabotulinumtoxinAhttps://modernaesthetics.com/news/top-line-phase-3-data-promising-for-galdermas-relabotulinumtoxina/2473250/Galderma’s investigational RelabotulinumtoxinA, a novel liquid formulation botulinum toxin A, improves both glabellar and lateral canthal lines with a rapid onset of action and a long duration up to six months, according to top-line phase 3 data presen
- BeautyHealth Appoints Bluemercury Founder Marla Beck to Board of Directorshttps://modernaesthetics.com/news/beautyhealth-appoints-bluemercury-founder-marla-beck-to-board-of-directors/2473249/Bluemercury founder Marla Beck is now a member ofThe Beauty Health Company’s Board of Directors. As founder and former CEO of Bluemercury, the disruptive omnichannel beauty retailer founded in 1999 and acquired by Macy’s in 2015, Ms. Beck has a track record of building
- Dr. Paul M. Friedman Named New ASLMS Presidenthttps://modernaesthetics.com/news/dr-paul-m-friedman-named-new-aslms-president/2473244/Paul M. Friedman, MD is the new President of the American Society for Laser Medicine and Surgery (ASLMS). Dr. Friedman, board-certified by the American Board of Dermatology, is the director of Dermatology & Laser Surgery Center of Houston
- Rion Aesthetics Initiates Series Ahttps://modernaesthetics.com/news/rion-aesthetics-initiates-series-a/2473241/With the initiation of Series A funding, Rion Aesthetics presents a unique investment opportunity for aesthetic providers. Rion plans on closing the Series A in the second quarter of 2022. Rion, a regenerati
- ISHRS Survey: Surgical Advances; Improvements in Efficiency Driving Need for Fewer Hair Transplant Treatmentshttps://modernaesthetics.com/news/ishrs-survey-surgical-advances-improvements-in-efficiency-driving-need-for-fewer-hair-transplant-treatments/2473235/According to results of a new member survey conducted by the International Society of Hair Restoration Surgery (ISHRS), 68 percent of members reported performing an average of one procedure per patient in 2021 to achieve the desired hair restoration result. This represents a significant improveme
- New from Lumenis: triLift Targets Three Elements of Aginghttps://modernaesthetics.com/news/new-form-lumenis-trilift-targets-three-elements-of-aging/2473227/Lumenis Be, Ltd., has launched triLift, a facial stimulation device targeting three aging elements—structure, contour, and texture—by treating the three tissue layers. The device affects the muscl
- R2 Technologies Ships 100 GLACIAL Deviceshttps://modernaesthetics.com/news/r2-technologies-ships-100-glacial-devices/2473224/R2 Technologies Inc. has shipped 100 GLACIAL Rx devices across the globe. To-date customers have delivered more than 15,000 GLACIAL treatment cycles, helping patients reach their skin goals by reducing inflammation and revealing younger looking skin. R2 reached this mileston
- Revance News: FDA Accepts BLA Resubmission for DaxibotulinumtoxinAhttps://modernaesthetics.com/news/revance-news-fda-accepts-bla-resubmission-for-daxibotulinumtoxina/2473223/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont